Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Dejaco, C; Duftner, C; Wipfler, E; Schirmer, M.
A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation
Wien Med Wochenschr. 2009; 159(3-4): 70-75.
Doi: 10.1007/s10354-008-0590-3
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Dejaco Christian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Abatacept is the first drug in a new class of disease-modifying anti-rheumatic drugs known as selective modulators of T-cell costimulation. The efficacy of abatacept in the treatment of rheumatoid arthritis (RA) has been shown in several clinical phase II and phase III trials, wherein abatacept was used in monotherapy, either in combination with methotrexate (MTX) after MTX-failure, in combination with MTX after failure of anti-TNF-alpha therapy or in combination with TNF-alpha blockers. In addition, the combination of abatacept/MTX was directly compared with infliximab/MTX. Current data on abatacept demonstrate an encouraging safety profile of this drug. The number of adverse events in patients on abatacept is comparable to that in patients treated with other biologics. Severe infections, however, are more common in abatacept-treated patients than in placebo-treated patients. Opportunistic infections are rare in patients with abatacept and the frequency of malignancies is not higher than expected in RA-patients. Additional studies are now warranted to get more information on rare adverse events and long-term unwanted effects.
- Find related publications in this database (using NLM MeSH Indexing)
- Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use
- Antirheumatic Agents - adverse effects Antirheumatic Agents - therapeutic use
- Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - immunology
- Disease Progression -
- Drug Therapy, Combination -
- Humans -
- Immunoconjugates - adverse effects Immunoconjugates - therapeutic use
- Lymphocyte Activation - drug effects Lymphocyte Activation - immunology
- Methotrexate - adverse effects Methotrexate - therapeutic use
- Randomized Controlled Trials as Topic -
- T-Lymphocytes - drug effects T-Lymphocytes - immunology
- Tumor Necrosis Factor-alpha - antagonists and inhibitors